Incyte Corporation - Common Stock (INCY)
109.03
+0.00 (0.00%)
NASDAQ · Last Trade: Feb 10th, 9:00 AM EST
Detailed Quote
| Previous Close | 109.03 |
|---|---|
| Open | - |
| Bid | 103.50 |
| Ask | 105.00 |
| Day's Range | N/A - N/A |
| 52 Week Range | 53.56 - 112.29 |
| Volume | 41,440 |
| Market Cap | 24.25B |
| PE Ratio (TTM) | 18.48 |
| EPS (TTM) | 5.9 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,830,532 |
Chart
About Incyte Corporation - Common Stock (INCY)
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for patients with serious diseases, particularly cancer and other unmet medical needs. The company leverages its expertise in molecular biology and drug development to create targeted treatments that aim to improve patient outcomes. With a strong emphasis on research and clinical trials, Incyte strives to advance its pipeline of potential medications, which includes both its proprietary compounds and collaborations with other pharmaceutical partners. Through its commitment to scientific excellence and patient-centric approaches, Incyte aims to address significant healthcare challenges and enhance the quality of life for individuals suffering from complex conditions. Read More
News & Press Releases
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 27.8% year on year to $1.51 billion. Its non-GAAP profit of $1.80 per share was 6.1% below analysts’ consensus estimates.
Via StockStory · February 10, 2026
Which S&P500 stocks are moving before the opening bell on Tuesday?chartmill.com
Via Chartmill · February 10, 2026
Incyte Corp. (NASDAQ:INCY) Reports Mixed Q4 2025 Results with Revenue Beat and EPS Misschartmill.com
Via Chartmill · February 10, 2026
Incyte (Nasdaq:INCY) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided full year 2026 financial guidance.
By Incyte · Via Business Wire · February 10, 2026
Value Investing Opportunity: Incyte Corp. (NASDAQ:INCY) Presents a Compelling Casechartmill.com
Via Chartmill · January 31, 2026
Incyte Corp. (NASDAQ:INCY) Emerges as a Compelling Value Stock with Strong Fundamentalschartmill.com
Via Chartmill · January 7, 2026
Incyte Corp (NASDAQ:INCY) Shows High-Growth Momentum and Strong Technical Trendchartmill.com
Via Chartmill · January 5, 2026
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY)
will be announcing earnings results this Tuesday before market open. Here’s what to look for.
Via StockStory · February 8, 2026
Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 10, 2026.
By Incyte · Via Business Wire · January 27, 2026
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Via StockStory · January 26, 2026
Which S&P500 stocks are moving on Friday?chartmill.com
Via Chartmill · January 23, 2026
Friday's session: gap up and gap down stock in the S&P500 indexchartmill.com
Via Chartmill · January 23, 2026
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Via StockStory · January 20, 2026
What's going on in today's session: S&P500 gap up and gap down stockschartmill.com
Via Chartmill · January 20, 2026
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Via StockStory · January 19, 2026
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Via StockStory · January 15, 2026
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY)
jumped 3.2% in the afternoon session after TD Cowen maintained a 'Buy' rating on the stock and increased its price target. The firm's analyst, Marc Frahm, lifted the price target from $101.00 to $128.00, a significant increase of nearly 27%. This adjustment signaled a strong positive outlook for the company's future stock performance. The action from the analyst suggested a heightened confidence in the biopharmaceutical company's value.
Via StockStory · January 14, 2026
What's going on in today's session: S&P500 moverschartmill.com
Via Chartmill · January 8, 2026
It's time once again for the Market Cap Game Show Holiday Edition, where intuition meets valuation and everyday life meets market caps.
Via The Motley Fool · January 8, 2026
A cash-heavy balance sheet is often a sign of strength, but not always.
Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Via StockStory · January 7, 2026
These S&P500 stocks are moving in today's sessionchartmill.com
Via Chartmill · January 7, 2026
Discover which S&P500 stocks are making waves on Wednesday.chartmill.com
Via Chartmill · January 7, 2026
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY)
jumped 3.7% in the morning session after the company announced positive top-line results from a late-stage study of its lymphoma drug, Monjuvi/Minjuvi (tafasitamab). The Phase III trial, called frontMIND, tested the drug as a first-line treatment for adults with a type of cancer known as diffuse large B-cell lymphoma (DLBCL). The study successfully met its main goal, showing a statistically meaningful improvement in how long patients lived without their disease getting worse. Based on these strong results, Incyte planned to submit a supplemental biologics license application to the FDA in the first half of 2026 to seek approval for this expanded use.
Via StockStory · January 7, 2026
Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years of age, or age-adjusted IPI (aaIPI) of two to three (2-3) for patients ≤60 years of age.
By Incyte · Via Business Wire · January 5, 2026
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Via StockStory · December 24, 2025